Trial Profile
A retrospective observational study of INOmax (nitric oxide) gas for inhalation in hospitalized COVID-19 patients with mild-to-moderate acute respiratory distress syndrome (ARDS) in the USA
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Apr 2022
Price :
$35
*
At a glance
- Drugs Nitric oxide (Primary)
- Indications Adult respiratory distress syndrome; COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- 20 Apr 2022 New trial record
- 13 Apr 2022 According to a Mallinckrodt plc media release, Steve Abman, M.D., Professor of Pediatrics at the University of Colorado is the lead study investigator.
- 13 Apr 2022 According to a Mallinckrodt plc media release, results of the study were published in the peer-reviewed journal Drugs in Context.